KRAS and tubular adenocarcinoma: While nearly all mutant Kras-driven GBC were classified as tubular adenocarcinomas, mutant ERBB2-driven GBCs were mostly of papillary/tubulo-papillary differentiation (Figure 4E, Table S1).